Here's the webinar:
My key takeaways:
- EMA are supportive of the current primary endpoints
- Plans to increase dosage
- Fat fraction may soon be a validated biomarker
In my mind it is almost a guarantee that we will see a phase IIb trial, considering that the team is considering raising the dose, there must be no safety concerns that might prevent the next trial. Once that trial is announced ANP's valuation will jump up considerably.
Here's the webinar:My key takeaways:- EMA are supportive of the...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
